Iqvia Holdings Inc.

IQV

NYSE; other; SIC 8731, Services-Commercial Physical & Biological Research; CIK 0001478242

D

fourth fifth of 315 graded peers in other

rank 229 of 315; percentile 72.6; sampling error 2.7 points; lower is stronger

A B C D E

D, the sloth



Scoreboard	
Profitability	C/D percentile 59.1
Solvency	C/D percentile 59.2
Growth and financing	C percentile 49.0
Reliability	0.94 AUC filers with over $2.67B assets; 95% interval 0.88 to 0.97; 61 events, 2020 to 2025
Peer failure rate	0.52% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	over $2.67B assets total assets $29.9B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered
Inputs computable	9 of 13
Graded from	filings received through Feb 17, 2026 279 days before the rescan; latest periodic filing 10-Q received Oct 27, 2026
Last close	$245.97 2026-11-20; market equity $40.5B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 17, 2026

IQVIA is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence? to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 59.1						
Gross profitability	not computable	26.7%				
one or more required annual facts are missing						
Return on invested capital	not computable	10.0%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Accruals ratio	(4.6%)	(5.7%)	59.1	458	2025-12-31
Gross margin stability, five years	not computable	2.2 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 59.2					
Altman Z double-prime	1.13	2.06	53.1	357	2025-12-31
Net debt to EBITDA	not computable	2.37x			
latest aligned inputs end 2017-12-31; latest annual assets end 2025-12-31					
Interest coverage	2.99x	2.93x	44.2	78	2025-12-31
Current ratio	0.75x	1.33x	80.5	462	2025-12-31
Growth and financing, sleeve percentile 49.0					
Revenue growth, three-year compound	4.2%	4.9%	50.4	376	2025-12-31
Free cash flow growth, three-year compound	8.9%	8.7%	46.7	213	2025-12-31
Reinvestment rate	(81.8%)	13.3%	83.9	187	2025-12-31
Asset growth, three years	5.7%	4.1%	40.6	402	2025-12-31
Net share issuance, one year	(3.6%)	(0.5%)	23.5	354	2026-02-06

Among 315 peers

other; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
224	Norfolk Southern Corp. (NSC)	71.0	D	
225	Aecom (ACM)	71.3	D	
226	Payoneer Global Inc. (PAYO)	71.7	D	
227	Alight, Inc. Delaware (ALIT)	72.0	D	
228	DLH Holdings Corp. (DLHC)	72.3	D	
229	Iqvia Holdings Inc. (IQV)	72.6	D	
230	Travel & Leisure Co. (TNL)	72.9	D	
231	Royal Caribbean Cruises Ltd. (RCL)	73.2	D	
232	Priority Technology Holdings, Inc. (PRTH)	73.6	D	
233	GEO Group Inc. (GEO)	73.9	D	
234	Monarch Casino & Resort Inc. (MCRI)	74.2	D	

What the price implies

at the 2026-11-20 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	24.2%	0.4%	71
Distance from 52-week high	(12.0%)	(28.8%)	79
EBIT to enterprise value	4.4%	4.6%	48
Free cash flow yield	5.1%	4.1%	57
Book value to price	0.16	0.39	26
Sales to price	0.40	0.75	33
Composite equity issuance, five years	(14.9%)	(9.5%)	43
Relative strength against the sector, log excess return	0.09	(0.12)	71

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Twelve-month failure probability, CHS model	0.03%	0.04%	28

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	pass
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$2.2B
Operating cash flow, four quarters	$2.7B
Months of runway	not finite
Days since last periodic filing	27 (10-Q received Oct 27, 2026)
Median daily dollar volume, 63 sessions	$358.0M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	operating income	us-gaap:OperatingIncomeLoss	$665.0M	2017-12-31	2020-02-18	10-K	20-004901
2	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$294.0M	2017-12-31	2020-02-18	10-K	20-004901
3	income tax	us-gaap:IncomeTaxExpenseBenefit	-$992.0M	2017-12-31	2020-02-18	10-K	20-004901
4	total debt	us-gaap:LongTermDebt	$10.3B	2017-12-31	2018-02-16	10-K	18-002340
5	book equity	us-gaap:StockholdersEquity	$8.0B	2017-12-31	2019-02-19	10-K	19-003180
6	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$959.0M	2017-12-31	2019-02-19	10-K	19-003180
7	total debt	us-gaap:LongTermDebtAndCapitalLeaseObligations	$7.1B	2016-12-31	2017-02-16	10-K	17-046709
8	book equity	us-gaap:StockholdersEquity	$8.6B	2016-12-31	2018-02-16	10-K	18-002340
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$1.2B	2016-12-31	2019-02-19	10-K	19-003180
10	net income	us-gaap:NetIncomeLoss	$1.4B	2025-12-31	2026-02-17	10-K	26-008322
11	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$2.7B	2025-12-31	2026-02-17	10-K	26-008322
12	assets	us-gaap:Assets	$29.9B	2025-12-31	2026-02-17	10-K	26-008322
13	assets	us-gaap:Assets	$26.9B	2024-12-31	2026-02-17	10-K	26-008322
14	current assets	us-gaap:AssetsCurrent	$6.2B	2025-12-31	2026-02-17	10-K	26-008322
15	current liabilities	us-gaap:LiabilitiesCurrent	$8.3B	2025-12-31	2026-02-17	10-K	26-008322
16	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	$7.4B	2025-12-31	2026-02-17	10-K	26-008322
17	operating income	us-gaap:OperatingIncomeLoss	$2.2B	2025-12-31	2026-02-17	10-K	26-008322
18	book equity	us-gaap:StockholdersEquity	$6.5B	2025-12-31	2026-02-17	10-K	26-008322
19	liabilities	us-gaap:Liabilities	$23.3B	2025-12-31	2026-02-17	10-K	26-008322
20	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$1.0B	2017-12-31	2020-02-18	10-K	20-004901
21	interest expense	us-gaap:InterestExpense	$729.0M	2025-12-31	2026-02-17	10-K	26-008322
22	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$16.3B	2025-12-31	2026-02-17	10-K	26-008322
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$15.4B	2024-12-31	2026-02-17	10-K	26-008322
24	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$15.0B	2023-12-31	2026-02-17	10-K	26-008322
25	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$14.4B	2022-12-31	2025-02-13	10-K	25-000045
26	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$603.0M	2025-12-31	2026-02-17	10-K	26-008322
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$2.7B	2024-12-31	2026-02-17	10-K	26-008322
28	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$602.0M	2024-12-31	2026-02-17	10-K	26-008322
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$2.1B	2023-12-31	2026-02-17	10-K	26-008322
30	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$649.0M	2023-12-31	2026-02-17	10-K	26-008322

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$2.3B	2022-12-31	2025-02-13	10-K	25-000045
32	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$674.0M	2022-12-31	2025-02-13	10-K	25-000045
33	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$1.1B	2025-12-31	2026-02-17	10-K	26-008322
34	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$1.6B	2025-12-31	2026-02-17	10-K	26-008322
35	income tax	us-gaap:IncomeTaxExpenseBenefit	$252.0M	2025-12-31	2026-02-17	10-K	26-008322
36	current assets	us-gaap:AssetsCurrent	$5.8B	2024-12-31	2026-02-17	10-K	26-008322
37	current liabilities	us-gaap:LiabilitiesCurrent	$7.0B	2024-12-31	2026-02-17	10-K	26-008322
38	assets	us-gaap:Assets	$26.7B	2023-12-31	2025-02-13	10-K	25-000045
39	assets	us-gaap:Assets	$25.3B	2022-12-31	2024-02-15	10-K	24-000038
40	shares outstanding	dei:EntityCommonStockSharesOutstanding	169,700,000	2026-02-06	2026-02-17	10-K	26-008322
41	shares outstanding	dei:EntityCommonStockSharesOutstanding	176,100,000	2025-02-05	2025-02-13	10-K	25-000045

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.